ESR1 and breast cancer: Treatment of ER+ breast cancer cells with FGFR inhibitors AZD4547 and PD173074 sensitized the cells to the anti-estrogen tamoxifen suggesting that targeting FGF10/FGFR2 may be a new approach to overcome resistance to hormone-deprivation therapy [203].